Edition:
India

Aslan Pharmaceuticals Ltd (6497.TWO)

6497.TWO on Gre Tai Securities Market of Chinese Taipei

20.65TWD
25 Jun 2019
Change (% chg)

NT$-0.40 (-1.90%)
Prev Close
NT$21.05
Open
NT$21.00
Day's High
NT$21.05
Day's Low
NT$20.35
Volume
272
Avg. Vol
451,977
52-wk High
NT$50.00
52-wk Low
NT$20.00

Latest Key Developments (Source: Significant Developments)

Aslan Pharmaceuticals Files For Offering Of 4.6 Mln American Depositary Shares Representing 23.1 Mln Ordinary Shares
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS LTD FILES FOR OFFERING OF 4.6 MILLION AMERICAN DEPOSITARY SHARES REPRESENTING 23.1 MILLION ORDINARY SHARES - SEC FILING.  Full Article

Aslan Pharmaceuticals Acquires Full Global Commercial Rights For ASLAN004 From CSL
Friday, 31 May 2019 

May 31 (Reuters) - Aslan Pharmaceuticals::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR ASLAN004 FROM CSL.ASLAN PHARMACEUTICALS-AMENDED LICENSE AGREEMENT WITH CSL SO CO HAS FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE .COMMERCIALISE ASLAN004 IN ALL INDICATIONS.ASLAN PHARMACEUTICALS LTD SAYS AMENDED AGREEMENT REPLACES LICENSING AGREEMENT ASLAN AND CSL SIGNED IN MAY 2014.ASLAN PHARMACEUTICALS-UNDER TERMS OF AMENDED AGREEMENT, CO TO MAKE FIRST PAYMENT OF US$30 MILLION TO CSL UPON COMMENCEMENT OF A PHASE 3 STUDY OF ASLAN004.ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE UP TO US$95 MILLION OF REGULATORY MILESTONES.ASLAN PHARMACEUTICALS - CSL IS ALSO ELIGIBLE TO RECEIVE $655 MILLION OF SALES MILESTONES, TIERED ROYALTIES ON NET SALES BETWEEN MID-SINGLE DIGITS AND 10%.  Full Article

Aslan Pharmaceuticals Qtrly Basic Loss Per Share $0.07
Friday, 22 Mar 2019 

March 22 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ASLAN PHARMACEUTICALS LTD QTRLY BASIC LOSS PER SHARE $0.07.ASLAN PHARMACEUTICALS - CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS TOTALED $28.9 MILLION AS OF DEC. 31, 2018 VERSUS $50.6 MILLION AS OF DEC. 31, 2017.  Full Article

‍Aslan Pharmaceuticals Files For Proposed IPO In U.S.​
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::‍ASLAN PHARMACEUTICALS FILES FOR PROPOSED INITIAL PUBLIC OFFERING IN U.S.​.‍ASLAN HAS APPLIED TO LIST ITS ADSS ON NASDAQ GLOBAL MARKET UNDER TRADING SYMBOL "ASLN"​.‍LEERINK PARTNERS AND PIPER JAFFRAY & CO. ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR THIS OFFERING​.  Full Article

Aslan Pharmaceuticals Files For U.S. IPO
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Aslan Pharmaceuticals Ltd ::ASLAN PHARMACEUTICALS LIMITED FILES FOR U.S. IPO OF UP TO $86.3 MILLION – SEC FILING.ASLAN PHARMACEUTICALS LIMITED SAYS IT INTENDS TO APPLY TO HAVE ITS ADS LISTED ON NASDAQ GLOBAL MARKET UNDER THE SYMBOL "ASLN".ASLAN PHARMACEUTICALS LIMITED SAYS LEERINK PARTNERS, PIPER JAFFRAY ARE AMONG UNDERWRITERS TO IPO.ASLAN PHARMACEUTICALS LIMITED SAYS BTIG, H.C. WAINWRIGHT & CO, CLSA ARE AMONG UNDERWRITERS TO IPO.ASLAN PHARMACEUTICALS LIMITED SAYS PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.  Full Article

Aslan Pharmaceuticals buys full global commercial rights for Varlitinib
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA.ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB​.ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS​.ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES.  Full Article

Aslan Pharmaceuticals unit to issue 67 mln new shares at T$38 per share
Monday, 13 Nov 2017 

Nov 13(Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO> ::Says its unit ASLAN Pharmaceuticals Pte. Ltd plans to issue 67 million new shares at T$38 per share .  Full Article

Aslan Pharmaceuticals plan private placement of up to 45 mln shares
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO> ::Says it plans to issue up to 45 million new shares via private placement, with details remaining to be determined .  Full Article